Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Fluphenazine(click to collapse)
1/4 selected
Fluphenazine
Prolixin
First-Generation Antipsychotic
FDA-approved indications
- Management of manifestations of psychotic disorders
Off-label uses
- Tourette syndrome
Half-life15 to 30 hours (decanoate: 7 to 10 days)
Decision GuideWhen to pick each / when to consider an alternative
Fluphenazine
Consider when
- Long-acting injectable for chronic non-adherence — fluphenazine decanoate every 2–4 weeks; longest-established FGA LAI
- Cost-constrained LAI needed — generic decanoate is most affordable LAI option after haloperidol decanoate
- High-potency FGA with established LAI track record — decades of outcome data in chronic schizophrenia maintenance
- Oral liquid formulation needed — oral elixir and concentrate available for observed dosing; useful in supervised settings
- +1 more
Consider an alternative when
- EPS-vulnerable patient — high D2 potency carries significant EPS and akathisia risk; comparable to haloperidol
- Tardive dyskinesia concern — FGA class carries highest TD risk; cumulative with duration; VMAT2 inhibitors if TD emerges
- Hyperprolactinemia concern — potent prolactin elevation; galactorrhea, amenorrhea, sexual dysfunction
- First-episode psychosis — SGAs preferred for better tolerability and metabolic monitoring; FGA LAI reserved for non-adherence
- +1 more
| Axis | Fluphenazine FGA |
|---|---|
| Boxed Warnings | |
Agranulocytosis / severe neutropenia | |
Cerebrovascular events (elderly w/ dementia) | |
Neuroleptic malignant syndrome (NMS) | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Akathisia / EPS | |
Tardive dyskinesia | |
Seizure risk | |
| Metabolic | |
Weight gain | |
| Endocrine | |
Prolactin elevation | |
| Autonomic | |
Anticholinergic burden | |
Orthostatic hypotension | |
| Cardiac | |
QTc prolongation | |
Heart rate / tachycardia | |
| GI | |
Nausea / GI (general) | |
| Hepatic | |
Liver enzymes / hepatotoxicity | |
| Dermatologic | |
Photosensitivity / skin pigmentation | |
| Sexual | |
Sexual dysfunction | |
| Interactions | |
CYP interactions / DDI profile | |
| Safety | |
Overdose toxicity | |
| Pregnancy | |
Teratogenicity | |
Lactation / breastfeeding safety | |